Lam M, Zhu JW, Tadrous M, et al. - Researchers examined the link between topical calcineurin inhibitor (TCI) use and risk of malignant neoplasms, vs nonactive and active comparator groups. For this systematic review and meta-analysis, observational studies assessing the link between treatment with TCIs (ie, tacrolimus and pimecrolimus) and the development of cancer with nonactive or active comparators were selected. Overall 11 studies were analyzed. Findings revealed no link between TCI use and risk of cancer overall or skin cancer. Treatment with TCI was associated with increased risk of lymphoma. Although a positive link between TCI use and lymphoma was evident in this study, the low absolute risk of lymphoma makes the potential elevated risk due to TCI use for any individual patient very small.